Skip to main content
    H

    Harvard Bioscience Inc (HBIO)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $8.31
    +0.16 (+1.96%)

    Market Cap: $37.10M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    49%(19/39)
    Avg Surprise
    -41.96%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.17
    Range$-0.31 - $-0.03
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.27+37.0%
    60d ago$-0.27+37.0%
    30d ago$-0.27+37.0%
    7d ago$-0.27+37.0%
    Current$-0.17
    Revenue Consensus
    $22M
    Range$22M - $22M
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.03
    Range$-0.21 - $0.27
    2 analysts
    Revenue Consensus
    $25M
    Range$25M - $26M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.03---
    Sep 26EST
    		-$-0.17---
    Jun 26
    Reported Aug 11
    		$-0.22$-0.21-4.76%Miss-120.0%
    Mar 26
    Reported May 12
    		$-0.77$-0.95+18.95%Beat-670.0%
    Dec 25
    Reported Mar 12
    		$-0.64$0.04-1695.75%Miss-1695.8%
    Sep 25
    Reported Nov 6
    		$-0.03$0.05-160.00%Miss+85.0%
    Jun 25
    Reported Aug 11
    		$-0.10N/A+60.00%Beat-48.6%
    Mar 25
    Reported May 12
    		$-0.10N/A+75.00%Beat-150.0%
    Dec 24
    Reported Mar 12
    		$0.04$0.05-20.00%Miss+0.0%
    Sep 24
    Reported Nov 7
    		$-0.20$0.15-233.33%Miss-300.0%
    Jun 24
    Reported Aug 8
    		$-0.07N/A-113.46%Miss-116.8%
    Mar 24
    Reported May 7
    		$0.20$0.25-20.00%Miss-66.7%
    Dec 23
    Reported Mar 7
    		$0.04$0.05-20.00%Miss+0.0%
    Sep 23
    Reported Nov 7
    		$0.10N/A-75.00%Miss+200.0%
    Jun 23
    Reported Aug 8
    		$0.40$0.55-27.27%Miss-20.0%
    Mar 23
    Reported Apr 25
    		$0.60$0.45+33.33%Beat+50.0%
    Dec 22
    Reported Mar 9
    		$0.04$0.03+33.33%Beat-50.0%
    Sep 22
    Reported Nov 8
    		$-0.10N/A-118.18%Miss-116.7%
    Jun 22
    Reported Aug 3
    		$0.50$0.55-9.09%Miss-16.7%
    Mar 22
    Reported May 4
    		$0.40$0.55-27.27%Miss-20.0%
    Dec 21
    Reported Mar 8
    		$0.08$0.10-20.00%Miss+0.0%
    Sep 21
    Reported Nov 3
    		$0.60$0.60+0.00%Beat+50.0%
    Jun 21
    Reported Aug 5
    		$0.60$0.65-7.69%Miss+20.0%
    Mar 21
    Reported May 6
    		$0.50$0.25+100.00%Beat+600.0%
    Dec 20
    Reported Mar 10
    		$0.08$0.07+14.29%Beat+0.0%
    Sep 20
    Reported Nov 5
    		$0.40$0.20+100.00%Beat+0.0%
    Jun 20
    Reported Aug 5
    		$0.50$-0.10+600.00%Beat+25.0%
    Mar 20
    Reported May 5
    		$-0.10N/A-133.33%Miss-150.0%
    Dec 19
    Reported Feb 26
    		$0.08$0.09-11.11%Miss+14.3%
    Sep 19
    Reported Nov 5
    		$0.40$0.50-20.00%Miss+0.0%
    Jun 19
    Reported Jul 25
    		$0.40$0.40+0.00%Beat-42.9%
    Mar 19
    Reported May 2
    		$0.20$0.35-42.86%Miss-33.3%
    Dec 18
    Reported Feb 28
    		$0.07$0.07+0.00%Beat+40.0%
    Sep 18
    Reported Oct 25
    		$0.40$0.40+0.00%Beat+33.3%
    Jun 18
    Reported Jul 26
    		$0.70$0.53+32.08%Beat+133.3%
    Mar 18
    Reported May 2
    		$0.30$0.27+11.11%Beat+50.0%
    Dec 17
    Reported Mar 1
    		$0.05$0.05+0.00%Beat+25.0%
    Sep 17
    Reported Oct 26
    		$0.30$0.33-9.09%Miss-
    Jun 17
    Reported Jul 27
    		$0.30$0.30+0.00%Beat-
    Mar 17
    Reported Apr 27
    		$0.20$0.13+53.85%Beat-
    Dec 16
    Reported Mar 9
    		$0.04$0.04+0.00%Beat-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00
    Payout Ratio0.00%
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio-5.01EV/EBITDA34.12x
    Price/FCF-33.61xFCF Yield-2.98%
    Profitability
    Profit Margin-11.90%Operating Margin-2.90%
    ROE-89.90%ROIC-8.28%
    Financial Health
    Debt/Equity4.94xInterest CoverageN/A
    Current Ratio1.87xQuick Ratio0.98x
    Trading Statistics
    Beta1.51Avg Volume16.50K
    52-Week High$9.4052-Week Low$3.75

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.32
    SMA 20$8.16
    SMA 50$7.73
    SMA 200$6.33
    EMA 10$8.24
    EMA 20$8.16
    EMA 50$7.73
    EMA 200$6.57

    MACD

    Line: 0.15Signal: 0.18Hist: -0.03

    ADX

    ADX: 36.5+DI: 16.9-DI: 18.0

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down60.0
    PSAR$8.78

    Bollinger Bands

    Upper Band$8.57
    Lower Band$7.75
    %B Position1007%(Upper)
    Band Width0.69

    RSI (14-Day)

    Neutral
    58.5

    Momentum Oscillators

    Stoch %K41.4
    Stoch %D40.8
    Williams %R-51.6
    ROC (10d)2.2%
    Momentum0.18
    CCI (20d)17.7
    MFI (14d)60.2

    Volatility Measures

    ATR (14d)$0.31(3.8%)
    StdDev (20d)0.21
    Hist Vol25.9%(Moderate)

    Volume Flow

    VWAP$8.22
    OBV944.0M
    AD Line61.5B
    CMF (20d)-0.021

    Volume Metrics

    Avg Vol (20d)17.1K
    Vol Ratio0.7x
    VWMA (20d)$8.13

    Pivot Points

    R3$8.85
    R2$8.61
    R1$8.38
    Pivot Point$8.14
    S1$7.91
    S2$7.67
    S3$7.44

    Advanced Oscillators

    TSI20.29
    Ultimate Osc40.1
    KST65.99

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$22.73M$20.75M$23.73M$20.59M$20.45M$21.77M$24.56M$21.97M$23.10M$24.51M$28.15M$25.36M
    Cost of Revenue$10.10M$8.51M$9.56M$8.57M$8.92M$9.59M$10.54M$9.21M$9.88M$9.74M$11.83M$10.64M
    Gross Profit$12.63M$12.24M$14.17M$12.02M$11.53M$12.18M$14.01M$12.77M$13.22M$14.77M$16.32M$14.73M
    Operating Expenses$13.61M$13.42M$12.46M$11.82M$12.35M$61.85M$14.00M$14.64M$15.29M$17.05M$16.04M$15.66M
    R&D$2.45M$2.33M$2.18M$2.13M$2.19M$2.32M$2.33M$2.57M$2.63M$2.88M$3.15M$2.76M
    SG&A$4.93M$4.94M$4.34M$4.22M$4.46M$5.45M$5.02M$5.22M$5.93M$6.93M$5.33M$5.81M
    Operating Income$-978,000$-1,174,000$1.71M$197,000$-819,000$-49,668,000$11,000$-1,874,000$-2,069,000$-2,279,000$282,000$-933,000
    Interest Income$-1,793,000$-1,728,000$-2,358,000$-966,000$-1,001,000$-933,000$-1,180,000$-856,000$-749,000$-751,000$-794,000$-882,000
    Interest Expense$1.92M$2.13M$4.91M$1.33M$1.44M$1.13M$0$2.62M$1.21M$2.21M$1.39M$0
    Income Before Tax$-2,896,000$-3,307,000$-3,204,000$-1,134,000$-2,254,000$-50,794,000$590,000$-4,491,000$-3,280,000$-4,484,000$-1,103,000$-562,000
    Income Tax Expense$14,000$117,000$-357,000$97,000$28,000$-454,000$572,000$311,000$-353,000$210,000$715,000$677,000
    Net Income$-2,910,000$-3,424,000$-2,847,000$-1,231,000$-2,282,000$-50,340,000$18,000$-4,802,000$-2,927,000$-4,694,000$-1,818,000$-1,239,000
    EBITDA$-871,000$217,000$1.13M$1.51M$-1,749,000$-48,075,000$3.63M$-1,731,000$-660,000$-1,882,000$1.54M$2.17M
    EBIT$-1,103,000$-1,579,000$-846,000$-168,000$-1,253,000$-49,861,000$1.77M$-3,635,000$-2,531,000$-3,733,000$-309,000$320,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HBIO

    Government Contracts

    Gov Obligations (TTM)
    $946434
    Gov Obligations / Revenue
    1.1%
    Obligations YoY
    -44.6%
    Active Awards
    21
    New Awards (TTM)
    12
    Avg Remaining Term
    1.6 mo

    Top agency: Department of Defense at 50.9% of trailing twelve month obligations across 3 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    HT942526FE008Department of DefenseDefense Health Agency$257744Dec 12, 2025
    1232SA25P0423Department of AgricultureAgricultural Research Service$242868Sep 22, 2025
    HT942525FE023Department of DefenseDefense Health Agency$129760Sep 2, 2025
    36C24726P0238Department of Veterans AffairsDepartment of Veterans Affairs$127063Jan 8, 2026
    1232SA25P0198Department of AgricultureAgricultural Research Service$108983Sep 22, 2025
    36C25026P0932Department of Veterans AffairsDepartment of Veterans Affairs$36366Jul 29, 2026
    HT942525FE030Department of DefenseDefense Health Agency$36356Oct 17, 2025
    HT009026FG1210011Department of DefenseDefense Health Agency$22768Dec 15, 2025
    HT009025FG0910036Department of DefenseDefense Health Agency$22430Sep 23, 2025
    HT009026FG1010038Department of DefenseDefense Health Agency$22386Oct 2, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Harvard Bioscience forms advisory board. Holder reports 5.20 percent in Harvard Bioscience stock

    Harvard Bioscience has formed a five-member scientific advisory board to guide its research, development, and new product roadmaps...

    ad-hoc-news.de•10/16/26•Somewhat-Bullish

    Harvard Bioscience forms advisory board. Holder reports 5.20 percent in Harvard Bioscience stock

    Harvard Bioscience announced the formation of a five-member Scientific Advisory Board on October 6, 2026, to guide its research, development, and new product roadmaps. This board...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Harvard Bioscience Q3 2026 Earnings Date and Estimates

    Harvard Bioscience (HBIO) is expected to release its Q3 2026 earnings on Tuesday, November 10, 2026, with a conference call scheduled for Thursday, November 5...

    MarketBeat•10/8/26•Somewhat-Bullish

    Harvard Bioscience Announces Creation of Scientific Advisory Board

    Harvard Bioscience, Inc. (Nasdaq: HBIO) announced the formation of its Scientific Advisory Board (SAB) to guide its research, development...

    GlobeNewswire•10/7/26•Somewhat-Bullish

    Harvard Bioscience creates scientific advisory board By Investing.com

    Harvard Bioscience (NASDAQ:HBIO) has announced the formation of a Scientific Advisory Board to guide its research, development, and new product strategies. The board will meet quarterly and comprises five members...

    Investing.com Nigeria•10/7/26•Somewhat-Bullish

    HBIO Valuation and Fair Value

    P/E
    -5.0x
    Forward P/E
    15.1x
    EV/EBITDA
    34.1x
    P/FCF
    -33.6x
    PEG
    1.3x
    P/B
    5.1x
    See GNG's fair value

    HBIO Profitability: Margins, ROIC and FCF

    Gross margin
    58.2%
    Operating margin
    -2.9%
    Net margin
    -11.9%
    ROIC
    -8.3%
    ROE
    -89.9%
    FCF margin
    -1.3%
    FCF yield
    -3.0%

    HBIO Competitors

    CompanyTicker
    Veru IncVERU
    Incannex Healthcare Inc.IXHL
    Nephros IncNEPH
    Star Equity Holdings IncSTRR
    Cosmos Health Inc.COSM
    Generation Bio CoGBIO
    FibroGen IncFGEN
    Edesa Biotech IncEDSA

    Sector: Healthcare

    HBIO Bull Case vs Bear Case

    Bull case

    • HBIO grew quarterly revenue 11.1% year over year.

    Bear case

    • HBIO has a -11.9% net profit margin.
    • HBIO beat EPS estimates in 37.5% of its last 8 reported quarters.
    • HBIO has a debt-to-equity ratio of 4.9x.

    HBIO Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -245.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.17
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    HBIO Dividend

    Forward yield
    0.0%
    Payout ratio
    0.0%

    Frequently Asked Questions About HBIO

    Does HBIO pay dividends?

    Harvard Bioscience Inc (HBIO) has a dividend payment track record. See the HBIO dividend history page for its current payment status, TTM yield, and recorded payments.

    What is HBIO's market cap?

    Harvard Bioscience Inc (HBIO) has a market capitalization of $37.10M with a current stock price of $8.31.

    Related stocks

    Sector: Healthcare

    All stocks starting with H

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In